Ultragenyx Pharmaceutical (RARE) Stock
Biotech company developing therapies for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Ultragenyx Pharmaceutical in August 2026.
Ultragenyx Pharmaceutical Inc (ticker: RARE) is a clinical‑stage and commercial biotechnology company focused on developing therapies for rare and ultra‑rare genetic diseases. With a market capitalisation of about $3.29bn, the firm combines marketed products with an active pipeline of biologics and gene‑therapy candidates. Key value drivers for the stock typically include clinical trial readouts, regulatory decisions, commercial uptake of approved products and partnering activity. Like many small‑to‑mid cap biotech companies, Ultragenyx can be exposed to high research and development costs, binary clinical outcomes and market volatility. Investors should be aware that values can fall as well as rise and that past performance is not a guide to the future. This summary is for general, educational purposes only and is not personalised financial advice; investors should perform their own research or consult a regulated adviser to assess suitability for their individual circumstances.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ultragenyx stock, expecting its price to rise significantly.
Financial Health
Ultragenyx is performing well with strong revenue and profits, supported by high gross margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can create significant movement; these events are opportunities to learn about risk‑reward, though outcomes can be binary and unpredictable.
Commercial Traction Matters
Revenue growth from approved therapies and uptake by specialists can de‑risk the story; however, commercial execution and pricing pressures remain potential headwinds.
Partnering & Access
Collaborations and international expansion can extend reach and share costs, but dependency on partners and regulatory variance across markets add complexity and risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
